Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 701

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 701
---
, 4,750,553 shares and 4,540,059 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | ​ |   |                  5 | ​ |   |                 5 |
| Additional paid-in capital                                                                                                                                                                                                                                          | ​ |   |            748,660 | ​ |   |           742,085 |
| Accumulated deficit                                                                                                                                                                                                                                                 | ​ |   |           -747,933 | ​ |   |          -684,745 |
| Accumulated other comprehensive loss                                                                                                                                                                                                                                | ​ |   |                -25 | ​ |   |              -260 |
| Total stockholders’ equity                                                                                                                                                                                                                                          | ​ |   |                707 | ​ |   |            57,085 |
| Total liabilities and stockholders’ equity                                                                                                                                                                                                                          | ​ | $ |             51,329 | ​ | $ |           125,844 |

See Notes to Condensed Consolidated Financial Statements.

F- 2

CARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (amounts in thousands, excluding share and per share data) (unaudited)

| ​                                                                                          
 ​                                                                                          | ​ 
 ​ 
 ​ | ​                  
 Three Months Ended |                  ​ 
 September 30, 2024 | ​ | ​ |                  ​ 
 September 30, 2023 | ​ 
 ​ | ​                 
 Nine Months Ended |                  ​ 
 September 30, 2024 | ​ | ​ |                  ​ 
 September 30, 2023 | ​ 
 ​ |
|:-------------------------------------------------------------------------------------------|:--|:-------------------|-------------------:|:--|:--|-------------------:|:--|:------------------|-------------------:|:--|:--|-------------------:|:--|
| Revenue:                                                                                   | ​ | ​                  |                  ​ | ​ | ​ |                  ​ | ​ | ​                 |                  ​ | ​ | ​ |                  ​ | ​ |
| Collaborative revenue                                                                      | ​ | $                  |              1,298 | ​ | $ |              2,471 | ​ | $                 |              2,086 | ​ | $ |             10,631 | ​ |
| Commercial supply revenue                                                                  | ​ | ​                  |                  — | ​ | ​ |              1,252 | ​ | ​                 |                640 |